A major change in WHO CNS5 is the designation of IDH-wildtype and H3-wildtype astrocytic tumours as glioblastomas, even in the presence of low-grade histologic features if certain key molecular criteria are met. This evidence concerns the gene IDH1 and glioblastoma.